Table 3 Relative benefits and risks of diclofenac
| Â | Outcome | Unit | Assessment time point | Placebo | Celecoxib | Naproxen | Etoricoxib | Ibuprofen | Acetaminophen |
|---|---|---|---|---|---|---|---|---|---|
Benefits | Pain (VAS) | ΔCFB (mm) | 6 weeks | −13.5 (−16.7, −10.4) | −4.7 (−8.0, −1.4) | −3.4 (−7.0, 0.1) | −0.1 (−4.3, 4.0) | −3.2 (−7.9, 1.5) | −9.1 (−13.5, −4.7) |
ΔCFB (mm) | 12 weeks | −12.3 (−17.3, −7.4) | −5.1 (−10.2, −0.1) | −3.3 (−8.6, 1.8) | −3.3 (−9.1, 2.5) | −4.5 (−11.5, 2.4) | −8.0 (−16.6, 0.5) | ||
Physical functioning (VAS) | ΔCFB (mm) | 6 weeks | −7.7 (−11.9, −3.4) | 0.2 (−4.1, 4.6) | 2.8 (−1.7, 7.4) | 2.4 (−2.4, 7.3) | 1.2 (−4.5, 6.9) | −5.4 (−12.4, 1.8) | |
ΔCFB (mm) | 12 weeks | −4.5 (−12.4, 3.1) | 2.3 (−5.7, 10.5) | 6.0 (−2.2, 14.1) | 5.8 (−2.9, 14.3) | 3.3 (−5.9, 12.3) | −7.2 (−14.5, 0.3) | ||
PGA VAS | ΔCFB (mm) | 6 weeks | −15.3 (−25.4, −5.2) | −5.7 (−16.1, 4.7) | −6.3 (−17.1, 4.5) | −5.9 (−18.0, 6.0) | −3.7 (−14.7, 7.4) | NA | |
Risks | APTC | Rate ratio | Duration of study | NA | 1.1 (0.7, 1.8) | 0.9 (0.4, 2.0) | 1.0 (0.9, 1.2) | 0.9 (0.5, 1.6) | NA |
Major CV event | Rate ratio | Duration of study | NA | 1.2 (0.8, 1.8) | 0.9 (0.4, 1.9) | 1.1 (0.9, 1.3) | 1.1 (0.7, 1.9) | NA | |
Major GI event | Rate ratio | Duration of study | NA | 1.4 (0.8, 2.3) | 0.3 (0.2, 0.6) | 1.5 (1.3, 1.9) | 0.5 (0.3, 0.9) | NA | |
Withdrawal due to any reason | Rate ratio | Duration of study | 0.7 (0.6, 0.8) | 1.1 (1.0, 1.3) | 1.0 (0.8, 1.2) | 1.2 (1.0, 1.5) | 0.7 (0.6, 0.9) | 0.8 (0.6, 1.0) | |
Withdrawal due to adverse events | Rate ratio | Duration of study | 1.6 (1.3, 1.9) | 1.4 (1.2, 1.8) | 1.1 (0.9, 1.4) | 1.7 (1.3, 2.2) | 0.9 (0.7, 1.2) | 0.9 (0.6, 1.4) | |
Withdrawal due to lack of efficacy | Rate ratio | Duration of study | 0.4 (0.3, 0.4) | 0.8 (0.7, 1.0) | 0.9 (0.7, 1.1) | 0.9 (0.7, 1.1) | 0.7 (0.5, 0.9) | 0.6 (0.4, 0.8) |